Trial Profile

An Open-Label, Multicenter, Rollover Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 13 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gantenerumab (Primary)
Indications Alzheimer's disease
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms PostGraduate
Sponsors Roche

Most Recent Events

18 Feb 2024 This trial has been discontinued in Portugal (End date:2023-03-06), according to European Clinical Trials Database record.
04 Feb 2024 This trial has been discontinued in Italy,according to European Clinical Trials Database record
27 Apr 2023 This trial has been completed in Finland (End Date: 06 Mar 2023), according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com